Exhibit 99



RISK FACTORS



IN ADDITION TO THE OTHER INFORMATION CONTAINED OR INCORPORATED BY REFERENCE IN THIS REPORT, YOU SHOULD CONSIDER THE FOLLOWING FACTORS CAREFULLY IN EVALUATING US AND OUR
BUSINESS BEFORE MAKING AN INVESTMENT DECISION. IF ANY OF THE FOLLOWING RISKS OCCUR, OUR BUSINESS, FINANCIAL CONDITION, OR RESULTS OF OPERATIONS COULD BE MATERIALLY ADVERSELY AFFECTED.



OUR FUTURE GROWTH DEPENDS ON EXPANSION OF INTERNATIONAL REVENUES AND WE WILL BE SUBJECT TO INCREASED RISKS IN THE INTERNATIONAL
MARKETPLACE



We estimate that our Inovoject®system inoculates more than 80% of all eggs produced for the United States and Canada broiler poultry
markets. Given this market penetration, we expect only limited growth in the number of system installations and only minor system revenue growth in this market. Additionally, due to our market penetration and the significance of the United States
and Canada poultry markets to our revenue, any adverse conditions in these markets could have a material and adverse affect on our revenues. For this reason, we must expand our device installations and product sales in markets outside the United
States and Canada in order to realize significant overall revenue growth. In each of 2002 and 2001, sales outside of the United States accounted for 31% of our consolidated revenues, up from 29% in 2000. Lack of market acceptance of our devices and
in ovo (in the egg) products in these markets would adversely affect our revenue growth. Revenue growth outside the United States and Canada depends on gaining market acceptance of our devices and in ovo administration of
biological products in markets outside the United States and Canada to treat prevailing poultry diseases in those markets.



International sales are also subject to a variety of risks, including risks arising from the following:



| | currency fluctuations, trading restrictions, tariffs, trade barriers and taxes;
|- | -------------------------------------------------------------------------------



| | adverse changes in local investment or exchange control regulations, potential restrictions on the flow of international capital, and the possibility of expropriation, confiscatory
taxation or price controls; and
|- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| | economic and political conditions beyond our control, including country-specific conditions such as political instability, government corruption and civil unrest.
|- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------



OUR FUTURE GROWTH ALSO DEPENDS ON THE DEVELOPMENT AND MARKET
ACCEPTANCE OF NEW PRODUCTS



In addition to international expansion, we
need to develop and market new products in order to continue to generate increased revenues and growth of our business. We currently are developing, both independently and in collaboration with others, various products which address poultry health
and performance needs. These products are being designed to be delivered in ovo through the Inovoject®system or in conjunction with the Inovoject®system, and are in
various stages of development. There is no guarantee that any new products will be successfully developed and marketed. In addition, we have not initiated the regulatory approval process for some of these potential products, and we cannot assure you
that regulatory approval will be obtained. Our inability to develop new products or any delay in our development of them may adversely affect our revenue growth. Because of a number of factors, a new product may not reach the market without



---

lengthy delays, if at all. Some of the factors which may affect our development and marketing of new products include the
following:



| | our research and evaluations of compounds and new technologies may not yield product opportunities;
|- | ---------------------------------------------------------------------------------------------------



| | potential products may involve extensive and time-consuming clinical trials to demonstrate safety and effectiveness, and the results of such trials are uncertain;
|- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------



| | potential products may require collaborative partners and we may be unable to identify partners or enter into arrangements on terms acceptable to us;
|- | -----------------------------------------------------------------------------------------------------------------------------------------------------



| | we may not be able to contract for the manufacture of new products at a cost or in quantities necessary to make them commercially viable;
|- | -----------------------------------------------------------------------------------------------------------------------------------------



| | domestic and international regulatory approval of these products may not be obtained or may be obtained only with lengthy delays;
|- | ---------------------------------------------------------------------------------------------------------------------------------



| | we may not be able to secure additional financing that may be needed to bring a potential product to market;
|- | ------------------------------------------------------------------------------------------------------------



| | we may experience unexpected safety or efficacy concerns with respect to marketed products, whether or not scientifically justified, leading to adverse public reaction, product
recalls, withdrawals or declining sales;
|- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| | marketing products developed jointly with other parties may require royalty payments or other payments by us to our co-developers, which may adversely affect our profitability;
|- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| | we may be unable to accurately predict market requirements and evolving standards; and
|- | --------------------------------------------------------------------------------------



| | we may not be able to attract and retain sufficient numbers of qualified development personnel.
|- | -----------------------------------------------------------------------------------------------



We have developed and commercialized two products that work with the Inovoject®System: the Egg Remover®and Vaccine Saver®.
These two products have had initial success, however, there is no guarantee that acceptance of these products will continue to grow.



Embrex has initiated the United States Department of Agriculture (USDA) regulatory approval process with respect to our in ovococcidiosis vaccine, Inovocox.
Although this product has been submitted for registration there is no assurance that USDA approval will be obtained. Marketing this product in foreign countries will require us to pursue separate approvals from foreign regulatory agencies. We are
constructing an $11.6 million biological manufacturing facility to commercially produce the Inovocox product. In addition to USDA approval for the Inovocox product, our biological manufacturing facility must receive a separate USDA
approval to manufacture Inovocox. We cannot assure you that the facility will receive USDA approval to manufacture Inovocox. Delays in obtaining either product or manufacturing facility approvals may adversely affect the marketing of,
and the ability to receive revenues from Inovocox. Additionally, even if we receive USDA product and facility approvals, we cannot assure you that Inovocox will be sold in commercial quantities or that product sales will be sufficient to
offset our investment in development of the product and construction of the biological manufacturing facility.



We are also developing a device to separate poultry by gender while still in the egg. We cannot assure you that our development work will lead to a successful commercial device.



We have developed and commercialized a technology using our proprietary viral neutralizing factor (VNF®). Our Bursaplex®product uses this
technology. Bursaplex®has been sold in commercial quantities during the past six years,
however, there is no assurance that the product will continue to be sold in commercial quantities.



In July, 2001 we submitted a registration application to the United States Department of Agriculture (USDA) for Newplex. In May of 2003, the USDA approved the marketing of Newplex, our in ovoNewcastle disease vaccine, within the United States. Newplex is based on VNF technology, as is Bursaplex®.We are now seeking regulatory approval for Newplex in other key markets worldwide. Although this product has received USDA approval, there is no assurance that other registrations will be granted or that Newplex will be sold in commercial quantities.



2



---

There can be no assurance that we will successfully complete the development and commercialization of any new products or
that such products, if developed and commercialized, will meet revenue and profit expectations.



ECONOMIC FACTORS AFFECTING OUR CUSTOMERS MAY ADVERSELY AFFECT OUR FINANCIAL RESULTS



Our revenues principally come from sales and leases to the poultry industry. If there is a general economic decline in that industry, our operations and financial
condition could be materially and adversely affected. Also, domestic and global economic factors beyond our control may adversely impact our customers and, as a result, our revenues and earnings. Examples of these factors include the following:



| | fluctuations in the prices of energy and poultry feed;
|- | ------------------------------------------------------



| | disease outbreaks that adversely affect poultry production;
|- | -----------------------------------------------------------



| | market demand for poultry products, including the supply and pricing of alternative proteins;
|- | ---------------------------------------------------------------------------------------------



| | costs to comply with applicable laws and regulations, including those relating to environmental protection, food safety, market regulation and genetically modified organisms or
ingredients;
|- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| | product recalls and related adverse publicity and consumer reaction;
|- | --------------------------------------------------------------------



| | access to foreign markets together with foreign economic conditions, including currency fluctuations; and
|- | ---------------------------------------------------------------------------------------------------------



| | the extent to which our cost of products and operating expenses increase faster than contractual price adjustments with our customers.
|- | --------------------------------------------------------------------------------------------------------------------------------------



For example, if rising poultry feed prices increase the production costs of commercial
poultry producers or a foreign government bans the importation of U.S. chicken, these producers may reduce production. This decreased production could adversely impact our revenues, since a principal component of our revenues are fees charged to
customers for the number of eggs injected or processed by Embrex devices.



WE FACE RISKS OF RAPIDLY CHANGING TECHNOLOGY AND COMPETITION



We are involved in areas of technology which are subject to rapid and significant technological change. Competitors include independent companies that specialize in biotechnology as well as major chemical and pharmaceutical companies,
universities, and public and private research organizations. Many of our competitors are well established and have substantially greater marketing, financial, technological and other resources than we. With expiration of the Sharma Patent,
competitive in ovo delivery methods are under development and may gain commercial acceptance. The poultry biological business is especially competitive and dominated by a few very large companies with an established global presence. Also,
competitors may succeed in developing technologies and products that are more effective than any which have been or are being developed by us or which would render our technology and products obsolete or non-competitive. We may not be successful in
establishing or maintaining technological competitiveness. Increased competition could mean lower prices for our products, reduced demand for our products and a corresponding reduction in our ability to recover development, engineering and
manufacturing costs. Any of these developments could have an adverse effect on our business, results of operations and financial condition.



3



---

WE DO NOT MANUFACTURE ANY OF OUR PRODUCTS AND ARE CURRENTLY DEPENDENT ON A SINGLE CONTRACT MANUFACTURER FOR
INOVOJECT®AND EGG REMOVER®DEVICES, FOR VNF®PRODUCTION, AND FOR PRODUCTION OF BURSAPLEX®AND NEWPLEX



We currently do not have facilities for the production of our
devices and biological products. Therefore, we rely principally upon relationships with contract manufacturers. There can be no assurance that we can maintain manufacture and supply agreements on terms and at costs acceptable to us. We have various
relationships with manufacturers and suppliers, including those described below. The loss of any of these relationships could adversely affect our operating results. There are a number of risks associated with our dependence on third-party
manufacturers including:



| |  | reduced control over delivery schedules;
| | - | ----------------------------------------



| |  | ability to maintain inventories;
| | - | --------------------------------



| |  | quality assurance;
| | - | ------------------



| |  | manufacturing yields and costs;
| | - | -------------------------------



| |  | the potential lack of adequate capacity during periods of unanticipated demand;
| | - | -------------------------------------------------------------------------------



| |  | limited warranties on products supplied to us;
| | - | ----------------------------------------------



| |  | increases in prices and the potential misappropriation of our intellectual property;
| | - | ------------------------------------------------------------------------------------



| |  | catastrophic loss of production capacity due to property damage, either man made or by nature; and
| | - | --------------------------------------------------------------------------------------------------



| |  | the loss of these contract manufacturers due to financial circumstances in their respective businesses or their exit from the business lines that manufacture our devices and
products.
| | - | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



If our third-party manufacturers fail to provide us
with an adequate supply of finished products, our business would be harmed. We have no long-term contracts or arrangements with any of our vendors that guarantee product availability or the continuation of particular payment terms. In addition, we
are currently dependent on a single contract manufacturer for several of our key products as described below. Although we believe our relationship with each of the manufacturers is sound, we cannot assure you that we will continue to maintain
relationships with them or that they will continue to exist.



Inovoject®and Egg Remover®Systems



We rely on Precision Automation Company, Inc. (Precision) to fabricate all of our Inovoject®and Egg Remover®systems. While other machine fabricators exist and have constructed limited numbers of Inovoject®systems, we do not currently have alternative sources for production of either the Inovoject®or Egg Remover®systems. If Precision is unable to carry out its manufacturing obligations to our satisfaction, we may be unable to obtain alternative manufacturing, or to obtain such manufacturing
on commercially reasonable terms or on a timely basis. Any delays in the manufacturing process may adversely impact our ability to meet



4



---

commercial demands for Inovoject®and Egg Remover®system installations and delay receipt of revenues from those installations.



Biological Products



We obtain all of our requirements for the active ingredient in VNF®(Viral Neutralizing Factor) from SPAFAS, Inc. (SPAFAS), a subsidiary of Charles River Laboratories, Inc. Under our agreement with SPAFAS, we maintain appropriate inventory levels and place orders with SPAFAS to allow us to satisfy
anticipated customer demand for VNF®. The manufacture of our VNF®product must be performed in licensed facilities and is subject to USDA regulation. The regulatory
approval granted by the USDA for Bursaplex®in January 1997 specifically covers vaccines
produced with SPAFAS-manufactured VNF®. Although there are other manufacturers that may be
capable of manufacturing VNF®, we do not currently have alternative sources for production
of VNF®.



We obtain all of our requirements for Bursaplex®from Merial Select, Inc. (Select), a Merck and Aventis company, and all of our requirements for Newplex from Lohmann Animal Health International (LAHI). The manufacture of all
biological products must be performed in licensed facilities, under approved regulatory methods. As the USDA licensed manufacturers of record, Select holds the USDA permit for Bursaplex®and LAHI holds the USDA permit for Newplex. Although there are other manufacturers that may be capable of manufacturing avian viral vaccines, we do not currently
have alternative sources for production of either product.



If either SPAFAS,
Select or LAHI is unable to carry out their respective manufacturing obligations (described immediately above) to our satisfaction, we may be unable to obtain alternative manufacturing, or to obtain such manufacturing on commercially reasonable
terms or on a timely basis. A change of supplier for the Company could adversely affect our future operating results due to the time it would take a new supplier to obtain regulatory approval by the USDA of its production process or manufacturing
facilities. Current regulatory approvals in foreign countries are or will be based on product manufactured with SPAFAS VNF®or Bursaplex®as manufactured by Select
or Newplex as manufactured by LAHI. A change of
manufacturer would result in the need to reapply for regulatory approval in those countries and may lead to suspended sales of that product until new approvals could be secured. Any delays in securing new approvals would have an adverse effect on
our revenues and growth prospects. We cannot guarantee that we would be able to secure new approvals in every country or that such approvals would be granted in a timely fashion.



WE ARE DEPENDENT ON DISTRIBUTORS IN CERTAIN MARKETS



We market and distribute our devices principally by leasing and licensing the systems directly to hatcheries. In some markets, such as
Japan, we instead rely upon distributors for our devices. We also rely on third parties to market certain biological products, such as products containing VNF®, and we may enter into other arrangements in the future. There can be no assurance that we can maintain these relationships on terms
acceptable to us. The loss of any of these relationships could adversely affect our operating results. There are a number of risks associated with our dependence on distributors and other third parties including:



| |  | reduced control over regulatory efforts which may delay local regulatory approvals and thus market introduction;
| | - | ----------------------------------------------------------------------------------------------------------------



| |  | reduced control over marketing and sales efforts and in turn the extent of resulting market penetration or acceptance;
| | - | ----------------------------------------------------------------------------------------------------------------------



| |  | reduced control over distribution and related customer satisfaction; and
| | - | ------------------------------------------------------------------------



5



---

| |  | potential delays in distribution associated with securing new distributors, if current relationships are not maintained.
| | - | ------------------------------------------------------------------------------------------------------------------------



POULTRY HEALTH AND DISEASE FACTORS AFFECTING OUR CUSTOMERS MAY ADVERSELY AFFECT OUR
FINANCIAL RESULTS



Any widespread poultry health problem or disease
outbreak could have a negative impact on global poultry production. Our revenues and earnings derived from both the U.S. and international poultry industry could be materially and adversely affected. In addition, the emergence of new disease
variants, serotypes and strains in the domestic and/or global markets may reduce the efficacy of our biological products and result in reduced revenues and earnings.



THE LOSS OF KEY CUSTOMERS COULD ADVERSELY AFFECT OUR FINANCIAL RESULTS



Historically, a significant portion of our revenues has come from a relatively small number of customers. Tyson Foods, Inc. (Tyson)
accounted for approximately 19% of our consolidated 2002 revenues. Our top three customers, including Tyson, accounted for approximately 30% of our consolidated 2002 revenues, which is down from 32% in 2001 and 34% in 2000. We expect a similar level
of customer concentration to continue in future years. The poultry market is highly concentrated, with the largest poultry producers dominating the market. For example, in 2002, Tyson supplied approximately 22% of all broilers grown in the United
States. The concentration of our revenues with these large customers makes us particularly dependent on factors affecting those customers. If we lose a large customer and fail to add new customers to replace lost revenues, our operating results will
be materially and adversely affected. Also, if these customers reduce the number of eggs they produce at hatcheries, we will receive lower device revenues since our fees are based on the number of eggs injected.



IF WE LOSE THE PROTECTION OF OUR PATENTS AND PROPRIETARY RIGHTS, OUR FINANCIAL RESULTS
COULD SUFFER



Some of our products and processes used to produce our
products involve proprietary rights, including patents. We own some of the technologies employed in these processes, and some are owned by others and licensed to us. The Inovoject®system utilizes a process that was patented by the USDA in the United States. We held an exclusive license to this primary patent
(Sharma Patent), which expired in June 2002. We have supplemented the Sharma Patent with additional U.S. and foreign patents covering specific design features of the Inovoject®system. However, there is a risk that a competitive system could gain acceptance in the United States now that the Sharma Patent has
expired.



We believe that patent protection of materials or processes we
develop and any products that may result from the research and development efforts of our licensors and us are important to the commercial success of our products. The loss of the protection of these patents and proprietary rights could adversely
affect our business and our competitive position in the market. The patent position of companies such as ours generally is highly uncertain and involves complex legal and factual questions. Some of the reasons for this uncertainty include the
following:



| |  | To date, no consistent regulatory policy has emerged regarding the breadth of claims allowed in biotechnology patents. Consequently, there can be no assurance that patent
applications relating to our products or technology will result in patents being issued or that, if issued, the patents will afford protection against competitors with similar technology;
| | - | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



6



---

| |  | Some patent licenses held by us may be terminated upon the occurrence of specified events or become non-exclusive after a specified period;
| | - | -------------------------------------------------------------------------------------------------------------------------------------------



| |  | Companies that obtain patents claiming products or processes that are necessary for or useful to the development of our products could bring legal actions against us claiming
infringement (though we currently are not the subject of any patent infringement claim);
| | - | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  | Issuance of a valid patent does not prevent other companies from using alternative, non-infringing technology so we cannot be sure that any of our patents (or patents issued to
others and licensed to us) will provide significant commercial protection;
| | - | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  | We may not have the financial resources necessary to obtain patent protection in some countries or to enforce any patent rights we may hold;
| | - | --------------------------------------------------------------------------------------------------------------------------------------------



| |  | The laws of some foreign countries may not protect proprietary rights to the same extent as the laws of the United States, and many companies have encountered significant problems
in protecting their proprietary rights in these foreign countries;
| | - | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  | We may be required to obtain licenses from others to develop, manufacture or market our products. We may not be able to obtain these licenses on commercially reasonable terms, and
the patents underlying the licenses may be valid and enforceable; and
| | - | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  | We also rely upon unpatented, proprietary technology, which we may not be able to protect fully if others independently develop substantially equivalent proprietary information or
techniques, improperly gain access to our proprietary technology, or disclose this technology to others.
| | - | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



We attempt to protect our proprietary materials and processes by relying on trade secret laws and non-disclosure and confidentiality agreements with our employees and
other persons with access to our proprietary materials or processes or who have licensing or research arrangements with us. We plan to continue to use these protections in the future but we cannot be sure that these agreements will not be breached
or that we would have adequate remedies for any breach. Even with these protections, others may independently develop or obtain access to these materials or processes, which may adversely affect our competitive position.



If we are sued for infringing the patent or other proprietary rights of a third party, we
could incur substantial costs and diversion of management and technical personnel, whether or not the litigation is ultimately determined in our favor.



We have been involved in the patent litigation summarized below:



Embrex v. Service Engineering Corporation and Edward G. Bounds, Jr.



In September 1996, we filed a patent infringement suit against Service Engineering Corporation and Edward G. Bounds, Jr. in the U.S. District Court for the Eastern
District of North Carolina. We made the following claims against the defendants:



Their development of an in ovo injection device, designed to compete with our patented Inovoject®injection method, infringes at least one claim of U.S. Patent No. 4,458,630, exclusively licensed to us for the in ovo injection of vaccines into an avian embryo (the Sharma Patent); and



7



---

They violated the terms of a Consent Judgment and Settlement Agreement entered into with us in November 1995 in which
prior litigation was concluded with Service Engineering Corporation and Edward G. Bounds, Jr. agreeing not to engage in future activities violating the Sharma Patent.



We sought injunctive relief to prevent infringement of the Sharma Patent as well as monetary damages.



In November 1996, Service Engineering Corporation and Edward G. Bounds, Jr. responded to our
suit by asserting various affirmative defenses and denying the substantive claims in our complaint.



This suit concluded on July 30, 1998 with a jury verdict in favor of us, which verdict:



| | fully upheld the validity of all asserted claims of the Sharma Patent, finding that the defendants had willfully infringed all asserted claims of the patent;
|- | -------------------------------------------------------------------------------------------------------------------------------------------------------------



| | found that the defendants had breached the 1995 Consent Judgment and Settlement Agreement and that the breach was not in good faith; and
|- | ----------------------------------------------------------------------------------------------------------------------------------------



| | awarded us damages of $500,000 plus litigation expenses and court costs.
|- | ------------------------------------------------------------------------



The Court entered a Judgment in favor of us on September 28, 1998, which included a monetary award of $2,612,885 and an injunction prohibiting the defendants from
practicing methods claimed in, or otherwise infringing, the Sharma Patent. That injunction has expired with the expiration of the Sharma Patent in June of 2002.



On October 28, 1998, Service Engineering Corporation and Edward G. Bounds, Jr. filed a notice of appeal in the U.S. Court of Appeals for the Federal Circuit seeking a
reversal of the Judgment. In July 2000, the U.S. Court of Appeals for the Federal Circuit affirmed the district courts decision to award to Embrex litigation expenses plus costs valued at approximately $1.5 million. In addition, the appeals
court upheld the finding that Service Engineering Corporation and Edward Bounds had willfully infringed all asserted claims of the Sharma Patent. However, the appeals court vacated the award of direct infringement damages finding that the district
court erroneously awarded direct damages without proper evidence to support the award. Therefore, the appeals court remanded that award ($500,000 which was trebled) to the district court for further proceedings for determination of a reasonable
royalty for the infringement of the patented method by Service



Engineering
Corporation and Edward G. Bounds, Jr. These proceedings were opened on August 28, 2000, but were stayed early in 2001 pending the conclusion of a bankruptcy proceeding initiated by Edward G. Bounds, Jr.



THE LOSS OF KEY COLLABORATORS, SUPPLIERS AND OTHER KEY PARTIES COULD ADVERSELY AFFECT OUR
FINANCIAL RESULTS



We currently conduct our operations with various
third-party collaborators, suppliers, licensors or licensees. We plan to continue developing these relationships and believe our present and future collaborators, suppliers, licensors and licensees will perform their obligations under their
agreements with us, based on an economic motivation to succeed. However, financial or other difficulties facing these parties may affect the amount and timing of funds and other resources devoted by the parties under these agreements. For example,
the National Institute of Standards and Technology (NIST) has suspended an Advanced Technology Program (ATP) grant for stem cell research as a result of our collaborators removal from the project and the licensor, North Carolina State
University (NCSU), has terminated the technology license to our collaborator. In addition, disagreements may arise with these third parties which could delay or lead to the termination of the development or commercialization of new products, or
result in litigation or arbitration, which would be time



8



---

consuming and expensive. Thus, there is no assurance that we will develop any new products or generate any revenues from
these collaborative agreements.



WE ARE SUBJECT TO AN INHERENT RISK OF
PRODUCT LIABILITY



The development, manufacture, distribution and
marketing of our products involve an inherent risk of product liability claims and associated adverse publicity. These claims may be made even with respect to those products that are manufactured in licensed and approved facilities or that otherwise
possess regulatory approval for commercial sale. These claims could expose us to significant liabilities that could prevent or interfere with the development and marketing of our products. Product liability claims could require us to spend
significant time and money in litigation or pay significant damages. Although we currently maintain liability insurance which we believe is adequate to cover the Companys potential exposure in this area, there can be no assurance that the
coverage limits of our policies will be adequate. Such insurance is expensive, difficult to obtain and may not continue to be available on acceptable terms or at all.



GOVERNMENT REGULATION AND THE NEED FOR REGULATORY APPROVAL MAY ADVERSELY AFFECT OUR BUSINESS



Regulatory approval required in various areas of our business may adversely affect our
operations. The primary emphasis of these requirements is to assure the safety and effectiveness of our products. While the use of the Inovoject®system is not subject to regulatory approval in the United States, it may require regulatory approval by foreign agencies. Also,
research and development activities and the investigation, manufacture and sale of poultry health products are subject to regulatory approval in the United States by either the USDA or the United States Food & Drug Administration (FDA) and state
agencies, as well as by foreign agencies. Obtaining regulatory approval is a lengthy, costly and uncertain process. Approval by the USDA generally takes 1 to 3 years, while approval by the FDA may take 5 or more years. Various problems may arise
during the regulatory approval process and may have an adverse impact on our operations. Changes in the policies of U.S. and foreign regulatory bodies could increase the time required to obtain regulatory approval for each new product. Delays in
obtaining approval may adversely affect the marketing of, and the ability to receive revenues and royalties from, products developed by us. There is no assurance that any future products developed by us or by our collaborative partners will receive
regulatory approval without lengthy delays, if at all. Even when approved, regulators may impose limitations on the uses for which the product may be marketed and may continue to review a product after approving it for marketing. Regulators may
impose restrictions and sanctions, including banning the continued sale of the product, if they discover problems with the product or its manufacturer.



Pursuant to some of our licensing or joint development agreements, the licensees or joint developers bear the costs associated with the regulatory approval process for
some products. We plan to continue to enter into these types of agreements in the future. If we cannot generate sufficient funds from operations or enter into licensing or joint development agreements to develop products, we may not have the
financial resources to complete the regulatory approval process with respect to all or any of the products currently under development. We may need to obtain approval from appropriate regulators before we can sell our products in a particular
jurisdiction.



Other regulations apply or may apply to research and
manufacturing activities, including federal, state and local laws, regulations and recommendations relating to the following:



| |  | safe working conditions;
| | - | ------------------------



| |  | laboratory and manufacturing practices; and
| | - | -------------------------------------------



9



---

| |  | use and disposal of hazardous substances used in conjunction with research activities.
| | - | --------------------------------------------------------------------------------------



It is difficult to predict the extent to which these or other government regulations may adversely impact the production and marketing of
our products.



OUR INABILITY TO ATTRACT AND RETAIN KEY PERSONNEL COULD
ADVERSELY AFFECT OUR BUSINESS



We must continue to attract and retain
experienced and highly educated scientific and management personnel and advisors to be able to develop marketable products and maintain a competitive research and technological position. Competition for qualified employees among biotechnology
companies is intense. There can be no assurance that we will be able to continue to attract and retain qualified staff. The departure of any key executive or our inability to recruit and retain key scientific or management personnel could have an
adverse affect on our business, results of operations or financial condition. Our ability to replace key individuals may be difficult and may take an extended period of time because of the limited number of individuals in the biotechnology industry
with the breadth of skills and experience required to develop and commercialize products successfully. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate such individuals. We have obtained
insurance in the amount of $1,000,000 on the life of Randall L. Marcuson, our President and Chief Executive Officer, of which we are the sole beneficiary. This amount may not be sufficient to compensate us for the loss of his services.



IF WE CANNOT CONTINUE TO PROVIDE TIMELY SUPPORT AND MAINTENANCE TO OUR CUSTOMERS, OUR
BUSINESS MAY SUFFER



We are required to supply, support, and maintain
large numbers of Inovoject®systems at our customers hatcheries on a timely basis at
a reasonable cost to us. There can be no assurance that we will be able to continue to provide these services on a timely or cost-effective basis. If we are unable to do so, our customers may reduce their use of our products, which could adversely
affect our operating results.



WE HAVE ANTI-TAKEOVER DEFENSES THAT COULD
DISCOURAGE OR DELAY A TAKEOVER



Provisions of our certificate of
incorporation and bylaws could have the effect of discouraging or delaying an acquisition of our company. For example, the Board of Directors has the authority to issue up to 15,000,000 shares of Preferred Stock in one or more series and to
determine the designations, preferences and relative rights and qualifications, limitations or restrictions of the shares constituting any series of Preferred Stock, without any further vote or action by the shareholders. The issuance of Preferred
Stock by the Board of Directors could affect the rights of the holders of Common Stock. For example, an issuance could result in a class of securities outstanding that would have preferences with respect to voting rights and dividends and in
liquidation over the Common Stock, and could (upon conversion or otherwise) enjoy all of the rights applicable to Common Stock. The authority of the Board of Directors to issue Preferred Stock potentially could be used to discourage attempts by
others to obtain control of us through merger, tender offer, proxy contest or otherwise by making these attempts more difficult to achieve or more costly. The Board of Directors may issue the Preferred Stock without shareholder approval and with
voting and conversion rights which could adversely affect the voting power of the holders of Common Stock. No agreements or understandings currently exist for the issuance of Preferred Stock, and the Board of Directors has no present intention to
issue any Preferred Stock. We adopted a shareholder rights plan which could have the effect of discouraging a takeover of us. The rights plan, if triggered, would make it more difficult to acquire us by, among other things, allowing existing
shareholders to acquire additional shares at a substantial discount, thus substantially inhibiting the ability of an interested party to obtain control of the Company.



10